Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study
Cephalalgia · 2025
DOI: 10.1177/03331024251338178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2025. Verfasst von Emil Gozalov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Migraine Disorders, Neurofilament Proteins, Glial Fibrillary Acidic Protein. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Lundbeck Foundation.
Abstract (Originalsprache)
Objective
To determine whether serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) concentrations differ between adults with migraine and healthy controls.
Methods
This single-center, cross-sectional study was conducted from September 2020 to June 2022. Adults diagnosed with migraine and healthy controls were enrolled. Serum GFAP and NfL concentrations were quantified using an ultra-sensitive single-molecule array platform. Analyses were adjusted for potential confounders, including age, sex, body mass index and smoking status.
Results
We assessed serum samples from 603 participants with migraine and 154 controls. Serum GFAP concentrations were 6.8% higher in the overall migraine group compared to controls (95% confidence interval = 0.4–13.5%; P = 0.036). Conversely, serum NfL concentrations did not differ between participants with migraine and controls (difference: −1.4%; 95% confidence interval = −7.9 to 5.6%; p = 0.68). Neither serum GFAP, nor NfL concentrations varied according to migraine subtype or headache status at the time of blood sampling.
Conclusions
Our findings demonstrate a modest yet statistically significant increase in serum GFAP among adults with migraine, independent of migraine subtype, whereas serum NfL levels were comparable to those of controls. Further research is needed to clarify the neurobiological mechanisms underlying elevated serum GFAP in migraine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Translational Research Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
- Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Glostrup, Denmark.
- Department of Biochemistry and Immunology, Lillebaelt Hospital, University Hospital of Southern Denmark, Vejle, Denmark.
- Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.
ORCID-Profile: Emil Gozalov, William K Karlsson, Rune H Christensen, Haidar M Al-Khazali, Jonna S Madsen, Messoud Ashina, Håkan Ashina
Förderung
- the Lundbeck Foundation
Zitieren
APA
Gozalov, E., Karlsson, W. K., Christensen, R. H., Al-Khazali, H. M., Hansen, M. B., Olsen, D. A., Søndergaard, H. B., Sellebjerg, F., Madsen, J. S., Ashina, M., & Ashina, H. (2025). Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study. Cephalalgia. https://doi.org/10.1177/03331024251338178
Vancouver
Gozalov E, Karlsson WK, Christensen RH, Al-Khazali HM, Hansen MB, Olsen DA, et al. Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study. Cephalalgia. 2025. doi:10.1177/03331024251338178
BibTeX
@article{Gozalov2025,
author = {Gozalov, Emil and Karlsson, William K and Christensen, Rune H and Al-Khazali, Haidar M and Hansen, Malene B and Olsen, Dorte A and Søndergaard, Helle B and Sellebjerg, Finn and Madsen, Jonna S and Ashina, Messoud and Ashina, Håkan},
title = {Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251338178}
}
EUVIMED